XBIO
$0.92
Xenetic Biosciences
($.01)
(1.15%)
XBIO
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.18)
Revenue:  $0.06 Mil
Friday
Nov 13
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when XBIO reports earnings?
Beat
Meet
Miss

Where is XBIO's stock price going from here?
Up
Flat
Down
Stock chart of XBIO
Analysts
Summary of analysts' recommendations for XBIO
Score
Grade
Pivots
Resistance
$1.06
$1.02
$0.97

$0.93

Support
$0.88
$0.84
$0.79
Tweet
Growth
Description
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.